Steven Breazzano
Long/short equity, deep value, contrarian

Prothena: Recent Sell-Off On Positive Data Creates Buying Opportunity

Prothena Corporation (NASDAQ:PRTA) is an early-stage, biotechnology company developing targeted antibody-based therapies for patients with AL amyloidosis, Parkinson's disease, and inflammatory / oncology conditions. Prothena's business is derived from Elan Pharmaceuticals (developers of now Biogen's successful Tysabri), and consists of a substantial portion of Elan's former drug discovery business platform, as well as its management team. PRTA's shares began trading on the NASDAQ on December 21, 2012 at $8/share. Since then, the shares have risen to as high as $49/share on the initial release of positive Phase 1 data for lead candidate NEOD001 in patients with amyloidosis in mid-March. Recently, the shares have fallen dramatically to approximately $21/share on the release of additional, patient level data of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details